Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kerberos Proximal Solutions Inc.

Latest From Kerberos Proximal Solutions Inc.

Singapore Offers Gateway to Asian Health Care Markets

The growth of markets within Asia is creating an enticing lure for medical device, pharmaceutical, and biomedical companies seeking to establish or enhance their presence in the region. Countries with large populations-and, in some cases, underserved medical needs for certain conditions-represent an opportunity to expand health care treatments. The government of Singapore is working hard to make sure foreign companies understand the island nation is very willing to offer that expertise and create an ideal location that could serve as a gateway to all of Asia.

Medical Device Middle East and Africa

What Happens After the Device IPO?

Investors love to remind everyone that IPOs are financing events, not exiting events, using the mantra to put off Judgment Day for their investments. So how have device companies fared after the recent spate of IPOs?

Business Strategies

Coronis: Creating Virtual Companies

Launched by four veterans of the medical device industry, Coronis Medical hopes to be able to nurture precisely the kind of opportunities that even the most early stage-minded of venture investors can't. Through its relationship with Stellartech, a design and development consulting firm, Coronis will be able to provide a wide array of services for the projects it takes on, creating virtual companies through what is, in effect, a kind of virtual incubator.

Business Strategies Business Strategies

FoxHollow and Merck Expand Alliance, Aim at Vulnerable Plaque

What's the value of a well-documented set of clinical samples in the atherosclerosis business? For Merck, about $150 million. For FoxHollow, funding and validation for its contrarian device model.

See All

Company Information

  • Industry
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive